Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y(14) receptor

作者:Kiselev Evgeny; Balasubramanian Ramachandran; Uliassi Elisa; Brown Kyle A; Trujillo Kevin; Katritch Vsevolod; Hammes Eva; Stevens Raymond C; Harden T Kendall; Jacobson Kenneth A*
来源:Bioorganic & Medicinal Chemistry Letters, 2015, 25(21): 4733-4739.
DOI:10.1016/j.bmcl.2015.08.021

摘要

The P2Y(14)R is a G(i/o)-coupled receptor of the P2Y family of purinergic receptors that is activated by extracellular UDP and UDP-glucose (UDPG). In an earlier report we described a P2Y(14)R fluorescent probe, MRS4174, based on the potent and selective antagonist PPTN, a naphthoic acid derivative. Here, we report the design, preparation, and activity of an agonist-based fluorescent probe MRS4183 (11) and a shorter P2Y(14)R agonist congener, which contain a UDP-glucuronic acid pharmacophore and BODIPY fluorophores conjugated through diaminoalkyl linkers. The design relied on both docking in a P2Y(14)R homology model and established structure activity relationship (SAR) of nucleotide analogs. 11 retained P2Y(14)R potency with EC50 value of 0.96 nM (inhibition of adenylyl cyclase), compared to parent UDPG (EC50 47 nM) and served as a tracer for microscopy and flow cytometry, displaying minimal nonspecific binding. Binding saturation analysis gave an apparent binding constant for 11 in whole cells of 21.4 +/- 1.1 nM, with a t(1/2) of association at 50 nM 11 of 23.9 min. Known P2Y(14)R agonists and PPTN inhibited cell binding of 11 with the expected rank order of potency. The success in the identification of a new P2Y(14)R fluorescent agonist with low nonspecific binding illustrates the advantages of rational design based on recently determined GPCR X-ray structures. Such conjugates will be useful tools in expanding the SAR of this receptor, which still lacks chemical diversity in its collective ligands. Published by Elsevier Ltd.

  • 出版日期2015-11-1